EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost‐Effectiveness of Hepatitis C Virus Case Finding and Treatment in Eastern Europe and Central Asia

Josephine G Walker iD, Irina Tskhomelidze Schumacher iD, Adam Trickey iD, Peter Vickerman iD

Liver International · 2025

DOI: 10.1111/liv.70199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Josephine G Walker und 3 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Medical School, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Substance Abuse, Intravenous, Mass Screening. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims In 2024, < 10% of hepatitis C virus (HCV) cases were treated in Eastern Europe and Central Asia (EECA) and the burden remains high. We aimed to estimate the cost‐effectiveness of treating anyone with HCV (‘treat all’) or targeting people who inject drugs (PWID) in 14 middle‐income EECA countries.

Methods

We gathered costs of screening, confirmatory tests, direct‐acting antiviral (DAA) treatment and monitoring from published country‐specific data, Georgian costs from previous analyses, and UNICEF. We combined decision tree modelling with a dynamic transmission model of HCV calibrated for each EECA country to calculate quality‐adjusted life years (QALYs) gained by 2030 from 100 DAA treatments in 2024, for treat all compared to targeting PWID. We calculated incremental cost‐effectiveness ratios (ICERs, cost per QALY gained) relative to gross domestic product (GDP) per capita.

Results

QALYs gained from 100 treatments ranged from 29‐55 if treat all and 25–90 if targeting PWID. Using country‐level costs, Bulgaria and Russia had ICERs above GDP per capita due to high DAA costs. For other countries, ICERs ranged from 18% to 89% of GDP (treat all) and 4%–89% (PWID). Using lower Georgian costs and UNICEF costs, the treat all ICERs were below 84% and 24% of GDP for all countries, respectively, except Bosnia, while the ICERs when targeting PWID were below 64% and 16% of GDP, respectively.

Conclusions

Strategies that treat all persons with HCV and target PWID are both likely to be cost‐effective in middle‐income EECA countries, particularly with broad access to low‐cost generic treatments such as through UNICEF procurement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis CSubstance Abuse, IntravenousMass ScreeningHumansCost-Benefit AnalysisEurope, EasternQuality-Adjusted Life YearsAsia, CentralDecision TreesHepacivirus

Stichwörter der Autor:innen

Europeblood‐borne infectionshepatitis Cinjecting drug usersmodellingviral infections

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Bristol Medical School, University of Bristol, Bristol, UK.
  • Task Force for Global Health, Tbilisi, Georgia.

ORCID-Profile: Josephine G Walker, Irina Tskhomelidze Schumacher, Adam Trickey, Peter Vickerman

Förderung

  • Gilead Sciences

Zitieren

APA

Walker, J. G., Schumacher, I. T., Trickey, A., & Vickerman, P. (2025). Cost‐Effectiveness of Hepatitis C Virus Case Finding and Treatment in Eastern Europe and Central Asia. Liver International. https://doi.org/10.1111/liv.70199

Vancouver

Walker JG, Schumacher IT, Trickey A, Vickerman P. Cost‐Effectiveness of Hepatitis C Virus Case Finding and Treatment in Eastern Europe and Central Asia. Liver International. 2025. doi:10.1111/liv.70199

BibTeX
@article{Walker2025,
  author = {Walker, Josephine G and Schumacher, Irina Tskhomelidze and Trickey, Adam and Vickerman, Peter},
  title = {Cost‐Effectiveness of Hepatitis C Virus Case Finding and Treatment in Eastern Europe and Central Asia},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70199}
}
Kostenlos starten →